Poor
Not Aligned
Patient Risk:
Moderate
Summary
Many claims about torsemide appear generally consistent with diuretic use, but several specific safety and monitoring claims about the combination with Lipitor (atorvastatin) are unsupported because the provided label excerpts only cover torsemide and do not address atorvastatin, drug-combination effects, myopathy, hepatitis, rhabdomyolysis, or acute liver failure.
Category Scores
Accurate Statements
Torsemide is a diuretic used to treat fluid build-up in the body.
DEMADEX is indicated for treatment of edema associated with congestive heart failure, renal disease, or hepatic disease (Section 1).
Generic versions of atorvastatin have been approved by the FDA and are available on the market.
Unsupported Statements
Combining torsemide and Lipitor may increase the risk of certain side effects due to their individual and combined effects on the kidneys and liver.
Provided torsemide label excerpts do not mention atorvastatin (Lipitor) or any combination-related kidney/liver risk.
Individuals with pre-existing kidney disease, especially severe kidney problems, may require closer monitoring of kidney function when taking torsemide and Lipitor together.
Torsemide label excerpt advises observation for electrolyte imbalance/hypovolemia/prerenal azotemia and periodic monitoring of serum potassium/electrolytes (Warnings), but it does not discuss kidney-function monitoring specifically for atorvastatin initiation or for the torsemide+Lipitor combination.
Both torsemide and Lipitor can impair kidney function.
Torsemide excerpt mentions prerenal azotemia risk and warns to stop if electrolyte imbalance/hypovolemia/prerenal azotemia occur, but it does not address Lipitor/atorvastatin.
The combination of torsemide and Lipitor may increase the risk of kidney damage or worsening kidney disease.
No atorvastatin-related content and no torsemide+atorvastatin combination nephrotoxicity claim in provided label excerpts.
When taken together, torsemide and Lipitor may increase the risk of muscle damage (myopathy).
No atorvastatin/myopathy content in torsemide label excerpts.
When taken together, torsemide and Lipitor may increase the risk of liver inflammation (hepatitis).
No atorvastatin hepatitis content in torsemide label excerpts.
In rare cases, the risk may lead to rhabdomyolysis (muscle breakdown).
No atorvastatin/rhabdomyolysis content in torsemide label excerpts.
In rare cases, the risk may lead to acute liver failure.
No atorvastatin acute liver failure content in torsemide label excerpts.
Regular kidney function tests may be recommended to monitor for potential kidney damage in kidney patients starting Lipitor.
No guidance in provided torsemide excerpt about kidney-function testing for Lipitor initiation; torsemide warnings focus on monitoring electrolytes/clinical evidence of imbalance.
Close monitoring of liver enzymes and cholesterol levels may be recommended.
Provided torsemide label excerpts do not mention cholesterol monitoring or liver-enzyme monitoring in relation to atorvastatin.
Dosage adjustments of either or both medications may be recommended to minimize the risk of adverse effects.
Torsemide label excerpts provide dosing/titration by indication but do not discuss dose adjustments based on combination with atorvastatin or to minimize atorvastatin-specific adverse effect risks.
Alternative treatments may be considered for high cholesterol and fluid build-up.
Torsemide label excerpts include only torsemide indications; they do not provide guidance on alternative treatments for high cholesterol or fluid build-up beyond torsemide-specific uses.
Alternatives to Lipitor may include bile acid sequestrants (e.g., cholestyramine).
No atorvastatin alternatives are addressed in torsemide label excerpts.
Alternatives to Lipitor may include nicotinic acid (niacin).
No atorvastatin alternatives are addressed in torsemide label excerpts.
Alternatives to Lipitor may include fibrates (e.g., fenofibrate).
No atorvastatin alternatives are addressed in torsemide label excerpts.
Alternatives to Lipitor may include omega-3 fatty acid supplements.
No atorvastatin alternatives are addressed in torsemide label excerpts.
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels in the blood.
The provided label excerpts are for torsemide (DEMADEX) only and do not include atorvastatin/Lipitor labeling.
Generic versions of atorvastatin have been approved by the FDA and are available on the market.
Not supported or addressed by the provided torsemide label excerpts.
Contradictions
Important Omissions
For torsemide, the label excerpt advises monitoring clinical evidence of electrolyte imbalance/hypovolemia/prerenal azotemia and periodic monitoring of serum potassium and other electrolytes; the AI response does not reflect these label-specific monitoring elements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response introduces multiple specific combination and atorvastatin-specific severe outcomes (myopathy, rhabdomyolysis, hepatitis, acute liver failure) and monitoring recommendations that are not supported by the provided torsemide FDA label excerpts, which could mislead labeling-consistency evaluation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Atorvastatin- and torsemide+atorvastatin-specific safety/monitoring claims are not supported by the provided FDA-approved torsemide labeling excerpts.
Suggested Improvement
Limit claims to what is supported in the provided DEMAX (torsemide) label excerpts (e.g., edema indications, torsemide dosing/titration, contraindications, and torsemide-specific warnings/monitoring such as electrolytes and prerenal azotemia). Do not attribute statin-specific adverse effects (myopathy/rhabdomyolysis/hepatitis/acute liver failure) or combination risk/monitoring to the torsemide label excerpts unless atorvastatin labeling is provided.